These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
14. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640 [TBL] [Abstract][Full Text] [Related]
15. The evolution of hematopoietic SCT in myelodysplastic syndrome. Kindwall-Keller T; Isola LM Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532 [TBL] [Abstract][Full Text] [Related]
16. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902 [TBL] [Abstract][Full Text] [Related]
17. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
19. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre]. Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537 [TBL] [Abstract][Full Text] [Related]
20. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]